Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 35Active not recruiting 28Completed 4Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 8Carboplatin 7Pemetrexed 5Nivolumab 5Cyclophosphamide 5Cisplatin 5ixazomib 4durvalumab 4Specimen Handling 4Paclitaxel 4Bevacizumab 4ibrutinib 3fludarabine phosphate 3fludarabine 3Ipilimumab 3Gemcitabine 3Docetaxel 3Cetuximab 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2temsirolimus 2evolocumab 2enzalutamide 2daratumumab 2atezolizumab 2Trastuzumab 2Tomography, X-Ray Computed 2Standard of Care 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × atezolizumab × 30 days × Clear all
NCT03520686 2026-05-26

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 3 Terminated
102 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡